BioCentury
ARTICLE | Company News

Strata, Clovis deal

February 10, 2017 9:18 PM UTC

Strata and Clovis partnered to accelerate patient enrollment in Clovis' TRITON program of Rubraca rucaparib. The program includes Phase II and III trials of Rubraca to treat metastatic castration-resistant prostate cancer. Strata will receive an undisclosed upfront fee and is eligible for per-patient fees and milestones. Strata will use its Strata Trial, an observational study that uses next-generation sequencing, to identify breast cancer early onset (BRCA) and ataxia telangiectasia mutated (ATM)-mutated advanced prostate cancer patients for the Phase II TRITON2 and Phase III TRITON3 trials. The companies declined to disclose additional financial terms...